O’Ryan Health and BlueSavant AI are teaming up to develop a first-of-its-kind blood test that uses RNA and AI to detect autism—earlier, faster, and from home.

Launching this spring, the study will enroll 200 children to validate BlueSavant AI’s model, which has already shown it can detect 88% of cases—3x better than current tools.

O’Ryan’s Artemis platform will power painless at-home blood collection, making it simple for families to take part.

This could redefine autism diagnosis—moving from behavior-based assessments to a science-backed blood test that gives families answers, faster.